PRN: What is the Market Forecast for the Drugs in Development for COVID-19

06/apr/2020 07:40:11 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.

What is the Market Forecast for the Drugs in Development for COVID-19

 
[06-April-2020]
 

Novel Coronavirus (COVID-19) Drugs in Development Market Forecast 2020-2030

Revenue Prospects by Type (Remdesivir, Chloroquine and Hydroxychloroquine, Ritonavir/Lopinavir, Ritonavir/Lopinavir + Interferon Beta, Others), Age Group (<10 Years, 10-19 Years, 20-29 Years, 30-80 Years, >80 Years) and Geography

LONDON, April 6, 2020 /PRNewswire/ -- As you know, Visiongain is a business information provider. One of our key aims is to help business grow â€�“ your business. It is also part of our remit to serve the companies that use us. We may not be able to develop a vaccine, but we can try and help the companies that do. And we will do that, by doing what we do â€�“ informing your industry.

Visiongain Logo

So please register NOW to receive your FREE, business information guide to the current and future market of vaccines being designed for COVID-19. If this report can help you and your organisation structure a potential drug, business case, or regional targeting of resources etc â€�“ then please let us know.

This is all we can do, to help you do what your company does.

Our 150+ page report provides 100+ tables, charts, and graphs. Read on to discover the most key areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Novel Coronavirus (COVID-19) Drugs in Development Market. See how to exploit the opportunities.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/novel-coronavirus-covid-19-drugs-in-development-market-forecast-2020-2030/#download_sampe_div

Forecasts to 2030 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the global market and submarkets
Along with revenue prediction for the overall world market, there are 2 segmentations of the Novel Coronavirus (COVID-19) Drugs in Development market, with forecasts for 5 Drugs, 5 Age Groups, each forecasted at a global and regional level.

Global Novel Coronavirus (COVID-19) Drugs in Development Market by Drugs
• Remdesivir
• Chloroquine and hydroxychloroquine
• Ritonavir/lopinavir
• Ritonavir/lopinavir + interferon beta
• Others

Global Novel Coronavirus (COVID-19) Drugs in Development Market by Age Group
• <10 Years • 10-19 Years • 20-29 Years • 30-80 Years • >80 Years

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 18 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe

Asia-Pacific
• Japan
• China
• India
• Taiwan
• South Korea
• Rest of Asia-Pacific

Rest of the World

The report also includes profiles and for some of the leading companies in the Novel Coronavirus (COVID-19) Drugs in Development Market, with a focus on this segment of these companies' operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, U.S., UK, Germany, Italy, India and China in particular, will continue to achieve high revenue growth to 2030.

Leading companies and the potential for market growth
Overall world revenue for Novel Coronavirus (COVID-19) Drugs in Development will surpass $xx billion in 2020, our work calculates. We predict strong revenue growth through to 2030.

Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Novel Coronavirus (COVID-19) Drugs in Development Market report helps you
In summary, our 150+ page report provides you with the following knowledge:
• Revenue forecasts to 2030 for 2 segmentations of the Novel Coronavirus (COVID-19) Drugs in Development market, with forecasts for 5 Drugs, 5 Age Groups, each forecasted at a global and regional levelâ€�“ Discover the industry's prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2030 for 4 regional and 12 key national marketsâ€�“ See forecasts for the Novel Coronavirus (COVID-19) Drugs in Development market in North America, Europe, Asia-Pacific and Rest of the World.
• Prospects for established firms and those seeking to enter the marketâ€�“ including company profiles for 10 of the major companies involved in the Novel Coronav! irus (COV ID-19) Drugs in Development Market
• Find quantitative and qualitative analyses with independent predictionsâ€�“ Receive information that only our report contains, staying informed with this invaluable business intelligence.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to https://www.visiongain.com/report/novel-coronavirus-covid-19-drugs-in-development-market-forecast-2020-2030/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.com to discuss any customized research needs you may have.

Companies covered in the report include:

CanSino Biologics Inc
Entos Pharmaceuticals, Inc
Gilead
Inovio
King Abdullah International Medical Research Center
National Institute of Allergy and Infectious Diseases
Naval Medical Research Center
Novavax
Philipps University Marburg Medical Center
SAB Biotherapeutics Inc

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Top 26 Asthma & COPD Companies 2020-2030

Global Clinical Trial Management System Market Forecast 2020-2030

Clinical Trial Supply and Logistics Market for Pharma 2019-2029

Global ePharmacy Market 2018-2028

Global Influenza Vaccines Market Outlook 2019-2029

Global Live Vaccines Market Forecast 2020-2030

Global Vaccine Contract Manufacturing Market Report 2019-2029

Top 25 Vaccines Market Forecast to 2029

Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl